Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer ...

Sage Therapeutics, Inc. (SAGE) recently received an unsolicited bid proposal from Biogen Inc. (BIIB) to be purchased at around $7.22 per share. This represents a 30% premium to the price of the ...

Biogen and Sage Therapeutics are discontinuing further development of their drug Zurzuvae as a potential treatment for major depressive disorder, a move that follows last year’s FDA rejection of ...

Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own. The bid of $7.22 per share was a 30% premium to ...

Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from drug giant Biogen BIIB to acquire the remaining shares of SAGE. Per Sage ...

Shares of the biotech Sage Therapeutics were up nearly 40% on Monday after the company’s partner Biogen threw it a lifeline late Friday. Little has gone right for Sage in recent years, as its ...

Biogen Inc. BIIB submitted an unsolicited bid to acquire all of the outstanding shares of Sage Therapeutics Inc. SAGE that it does not already owned by Biogen for $7.22 per share. Goldman Sachs ...